NovaBay Pharmaceuticals, Inc.

Form 4

September 12, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to

Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

C/O NOVABAY

1. Name and Address of Reporting Person * Najafi Ramin

2. Issuer Name and Ticker or Trading Symbol

NovaBay Pharmaceuticals, Inc. [NBY]

3. Date of Earliest Transaction

09/12/2008

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

(Last) (First)

(Middle)

(Month/Day/Year)

_X__ Director 10% Owner _X__ Officer (give title __X__ Other (specify

below) below)

Chief Executive Officer / Chariman

PHARMACEUTICALS, INC,, 5980 **HORTON STREET, SUITE 550**

(Street)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

EMERYVILLE, CA 94608

(City)	(State)	(Zip) Tabl	e I - Non-I	Derivative	Secui	rities Acq	uired, Disposed	of, or Beneficia	ally Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securion(A) or Di (Instr. 3,	spose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	09/11/2008		Code V P	Amount 700	(D)	Price \$ 1.92	,	D	
Common Stock	09/11/2008		P	300	A	\$ 1.928	8,200	D	
Common Stock	09/12/2008		P	300	A	\$ 1.8	8,500	D	
Common Stock	09/12/2008		P	100	A	\$ 1.95	8,600	D	
	09/12/2008		P	100	A	\$ 1.94	8,700	D	

Common Stock

Common Stock

3,117,500

I

By the Najafi Family Trust dated September 13,2006 (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transaction	5. orNumber	6. Date Exerc Expiration D		7. Title Amour		8. Price of Derivative	9. Nu Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl	ying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ies	(Instr. 5)	Bene
	Derivative				Securities			(Instr. :	3 and 4)		Own
	Security				Acquired						Follo
	•				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
									or		
						Date	Expiration		Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
reporting owner rune, runeress	Director	10% Owner	Officer	Other				
Najafi Ramin C/O NOVABAY PHARMACEUTICALS, INC, 5980 HORTON STREET, SUITE 550 EMERYVILLE, CA 94608	X		Chief Executive Officer	Chariman				
Najafi Family Trust dated September 13, 2006 C/O NOVABAY PHARMACEUTICALS, INC. 5980 HORTON STREET, SUITE 550 EMERYVILLE, CA 94608		X						

2 Reporting Owners

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

Signatures

/s/ Theresa Granados, Attorney-in-Fact for Ramin Najafi 09/12/2008

**Signature of Reporting Person Date

/s/ Theresa Granados, Attorney-in-Fact for the Najafi Family Trust, dated September 13, 2006

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reminder: Report on separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3